<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cutaneous manifestations of graft-versus-host disease (GVHD)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cutaneous manifestations of graft-versus-host disease (GVHD)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cutaneous manifestations of graft-versus-host disease (GVHD)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edward W Cowen, MD, MHSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 02, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3496485">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute and chronic graft-versus-host disease (GVHD) are multisystem disorders that are complications of hematopoietic cell transplant (HCT). Skin involvement is common, and mucosal, hair, or nail abnormalities may also occur. Because these disorders share clinical and histopathologic features with a variety of other skin diseases, thorough consideration of the differential diagnosis is essential for the management of post-HCT patients with lesions suggestive of cutaneous GVHD.
        </p>
        <p>
         The clinical and histopathologic features, differential diagnosis, and supportive therapy of cutaneous GVHD will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of acute and chronic GVHD are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">
          "Pathogenesis of graft-versus-host disease (GVHD)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3542.html" rel="external">
          "Prevention of graft-versus-host disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">
          "Treatment of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2692898">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classically, GVHD has been divided into acute and chronic forms based upon the time of onset of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute GVHD – Manifestations of GVHD occurring within 100 days after hematopoietic cell transplant (HCT)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic GVHD – Manifestations of GVHD occurring more than 100 days after HCT
        </p>
        <p>
        </p>
        <p>
         However, this conventional division has been challenged by the recognition that signs of acute and chronic GVHD may occur outside of these designated periods. This observation has led to increasing use of clinical findings, rather than a set time period, to differentiate between acute and chronic GVHD [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Introduction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18902803">
         <span class="h1">
          ACUTE CUTANEOUS GRAFT-VERSUS-HOST DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute GVHD is common after allogenic hematopoietic cell transplant (HCT), and can lead to disorders of the skin, gastrointestinal tract, liver, and hematopoietic system. Cutaneous involvement is often the earliest manifestation of acute GVHD; skin lesions frequently appear within two to four weeks of HCT but may occur any time after hematopoietic cell engraftment. (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18902811">
         <span class="h2">
          Clinical manifestations
         </span>
        </p>
        <p class="headingAnchor" id="H878137">
         <span class="h3">
          Skin lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute cutaneous GVHD typically begins with erythematous, blanchable macules on the ears, palms, or soles  (
         <a class="graphic graphic_picture graphicRef72825" href="/z/d/graphic/72825.html" rel="external">
          picture 1
         </a>
         ). The lateral neck, cheek, and upper back are additional common sites of early involvement [
         <a href="#rid2">
          2,3
         </a>
         ]. Follicular-based lesions are present in some patients  (
         <a class="graphic graphic_picture graphicRef59686" href="/z/d/graphic/59686.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p>
         As acute cutaneous GVHD progresses, lesions become generalized, and the eruption often takes on a morbilliform (measles-like) appearance. Smooth or hyperkeratotic papules and postinflammatory hyperpigmentation may occur [
         <a href="#rid2">
          2,3
         </a>
         ]. In severe cases, patients develop atypical target lesions, generalized erythroderma, bullae, or extensive skin sloughing, resembling Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)  (
         <a class="graphic graphic_picture graphicRef66097" href="/z/d/graphic/66097.html" rel="external">
          picture 3
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Skin'
         </a>
         .)
        </p>
        <p>
         Patients with acute cutaneous GVHD may complain of pruritus or a burning sensation in the skin. In some patients, skin pain or pruritus precedes the onset of visible skin lesions [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         As with intestinal and hepatic GVHD, a staging system is used to describe the extent of cutaneous involvement  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 1
         </strong>
         – Less than 25 percent body surface area (BSA) involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 2
         </strong>
         – 25 to 50 percent BSA involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 3
         </strong>
         – Greater than 50 percent BSA involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 4
         </strong>
         – Erythroderma with bullae
        </p>
        <p>
        </p>
        <p>
         The combined stages of skin, liver, and gastrointestinal disease are used to determine the overall severity (grade) of acute GVHD  (
         <a class="graphic graphic_table graphicRef68233" href="/z/d/graphic/68233.html" rel="external">
          table 1
         </a>
         ). The presence of erythroderma and bullae (as may occur in SJS/TEN-like acute cutaneous GVHD) is sufficient to diagnose grade 4 GVHD and is associated with a poor prognosis [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H733754">
         <span class="h3">
          Oral lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythema, erosions, ulcers, lichenoid lesions, xerostomia, and pain involving the oral cavity have been attributed to acute GVHD [
         <a href="#rid4">
          4,7
         </a>
         ]. However, relatively little is known about oral acute GVHD due to difficulty in distinguishing this disorder from mucositis secondary to chemotherapy administered in preparation for HCT. Some authors have suggested that lesions that persist for longer than three weeks after HCT or involve the hard palate (an uncommon site for chemotherapy-induced mucositis) may be more likely to represent acute GVHD [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1152.html" rel="external">
          "Oral toxicity associated with systemic anticancer therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18902827">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of concomitant extracutaneous manifestations, making a definitive diagnosis of acute cutaneous GVHD may be challenging. The clinical findings are nonspecific and can be difficult to distinguish clinically from other skin eruptions that occur in post-HCT patients and there are no pathognomonic histopathologic features [
         <a href="#rid8">
          8
         </a>
         ]. Correlation between clinical and pathologic findings is essential. (See
         <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">
          "Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Diagnosis'
         </a>
         and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         A retrospective study of patients with acute cutaneous GVHD with SJS/TEN-like features (n = 15) or without these features (n = 16) found a higher rate of systemic complications, including hematologic abnormalities, hepatitis, diarrhea, renal dysfunction, and bacteremia, in patients with SJS/TEN-like acute cutaneous GVHD [
         <a href="#rid9">
          9
         </a>
         ]. Moreover, patients with SJS/TEN-like acute cutaneous GVHD had higher short-term mortality (death of three patients with SJS/TEN-like features within two months compared with no patients without SJS/TEN-like features) and higher five-year mortality (hazard ratio 5.351, 95% CI 1.838-15.580).
        </p>
        <p class="headingAnchor" id="H832193">
         <span class="h3">
          Skin biopsy
         </span>
        </p>
        <p class="headingAnchor" id="H3598346116">
         <span class="h4">
          Procedure and findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 4 mm punch biopsy sent for hematoxylin and eosin staining is generally sufficient to evaluate for acute cutaneous GVHD. Immunofluorescence testing may demonstrate nonspecific IgM and complement deposits at the basement membrane zone [
         <a href="#rid10">
          10
         </a>
         ] but generally is not indicated.
        </p>
        <p>
         Key histopathologic findings in acute cutaneous GVHD include interface dermatitis (vacuolization of the basal layer of the epidermis and a lymphocytic infiltrate in the superficial dermis) and epidermal apoptotic keratinocytes  (
         <a class="graphic graphic_picture graphicRef61055" href="/z/d/graphic/61055.html" rel="external">
          picture 4
         </a>
         ). Apoptotic keratinocytes may also be present in the follicular epithelium [
         <a href="#rid4">
          4,11
         </a>
         ]
        </p>
        <p>
         The lymphocytic infiltrate can be sparse and perivascular or more extensive. Migration of lymphocytes into the epidermis (lymphocyte exocytosis) is common. The presence of satellite cell necrosis (two or more lymphocytes surrounding an apoptotic keratinocyte) also supports a diagnosis of acute GVHD. Fulminant lesions demonstrate subepidermal clefting and full-thickness necrosis of the epidermis [
         <a href="#rid4">
          4,11
         </a>
         ].
        </p>
        <p>
         The criteria often used for categorizing the histopathologic findings in acute GVHD are as follows [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 0
         </strong>
         – Normal skin or changes not referable to GVHD
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 1
         </strong>
         – Vacuolization of the basal layer at the dermal-epidermal junction
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 2
         </strong>
         – Basal layer vacuolization, necrotic epidermal cells, lymphocytic infiltrate  (
         <a class="graphic graphic_picture graphicRef61055" href="/z/d/graphic/61055.html" rel="external">
          picture 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 3
         </strong>
         – Grade 2 changes plus cleft formation at the dermal-epidermal junction
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grade 4
         </strong>
         – Grade 2 changes plus separation of the epidermis from the dermis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4153143444">
         <span class="h4">
          Reliability and value
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sensitivity and specificity of skin biopsy for acute GVHD has not been definitively established. In general, a diagnosis of acute cutaneous GVHD is supported by the appearance of a consistent cutaneous eruption occurring in a time period that correlates with the return of neutrophils to the peripheral circulation (engraftment) and at least grade 2 changes on histopathologic examination [
         <a href="#rid13">
          13
         </a>
         ]. Biopsies taken early in the course of GVHD may reveal nondiagnostic findings. In one retrospective study of 40 biopsy specimens from 38 patients with skin eruptions taken between 3 and 21 days after HCT, the histopathologic findings were nonspecific in all cases [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         In addition, it is unclear whether skin biopsies influence the decision to treat or affect disease outcomes in patients with acute GVHD. Thus, the value of performing a skin biopsy, particularly early in the course of acute GVHD, has been questioned by some authors [
         <a href="#rid15">
          15-18
         </a>
         ]. Few studies have investigated the role of skin biopsies. The following studies found little evidence in support of this procedure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of 187 patients who had received allogenic HCT within the preceding 30 days found that the results of skin biopsies (performed in 51 patients who developed skin eruptions suggestive of GVHD) did not influence the likelihood of patients to receive treatment. In addition, skin biopsy results failed to correlate with clinical severity of skin disease [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of patients with a new skin eruption who were status post allogenic HCT, 98 skin biopsies from 71 patients with clinical grade 2 or higher acute GVHD were compared with 81 biopsies from 66 patients who did not progress to clinically significant acute GVHD [
         <a href="#rid18">
          18
         </a>
         ]. No single histopathologic finding was found to be a statistically significant diagnostic indicator of GVHD. The authors concluded that biopsies were of limited use for determining which patients will progress to grade 2 or higher GVHD.
        </p>
        <p>
        </p>
        <p>
         Despite the lack of strong evidence to support performing a skin biopsy in patients with suspected GVHD, a biopsy may provide information that can be used in conjunction with other clinical findings to support a diagnosis of acute GVHD or to establish an alternative cause of the skin eruption. Due to the relative safety of skin biopsy procedures and the known risks associated with immunosuppressive therapy used in the management of acute GVHD, many clinicians, including ourselves, continue to perform skin biopsies in post-HCT patients with skin eruptions for which the differential diagnosis includes acute GVHD. Additional studies are necessary to investigate the utility of skin biopsy in the management of acute GVHD and the most appropriate setting and timing for skin biopsy. Potential adverse effects of skin biopsy include minor bleeding, infection, and scarring.
        </p>
        <p class="headingAnchor" id="H733005">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple other disorders may present with clinical or histopathologic features that resemble acute GVHD. The following conditions should be considered [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug eruptions
         </strong>
         – Differentiation of acute GVHD from a drug eruption may not be possible  (
         <a class="graphic graphic_picture graphicRef54205" href="/z/d/graphic/54205.html" rel="external">
          picture 5
         </a>
         ). Morbilliform drug reactions typically develop 7 to 10 days after first exposure to the inciting medication; however, more rapid onset (within one to two days) may occur upon re-exposure to an offending agent. Unlike GVHD, which most commonly starts on the head, neck, and acral sites, morbilliform drug reactions typically begin on the torso and spread over several days to involve the lower extremities [
         <a href="#rid19">
          19,20
         </a>
         ]. Although the presence of eosinophils on biopsy is often associated with drug eruptions, the presence of eosinophils does not rule out GVHD [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">
          "Exanthematous (maculopapular) drug eruption"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antibiotics, particularly sulfonamides and beta-lactams, are the most common causes of drug eruptions in the post-HCT setting [
         <a href="#rid8">
          8
         </a>
         ]. Phototoxic drug eruptions secondary to
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         may also be mistaken for GVHD [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viral exanthems
         </strong>
         – Viral infections (eg, human herpesvirus [HHV] 6, HHV-7, cytomegalovirus, others) can induce maculopapular or morbilliform eruptions in post-HCT patients  (
         <a class="graphic graphic_picture graphicRef58169" href="/z/d/graphic/58169.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid2">
          2,8,23
         </a>
         ]. Skin biopsy specimens secondary to viral exanthems often demonstrate sparse perivascular lymphocytic infiltrates. Disease-specific clinical, laboratory, or histopathologic findings (eg, intranuclear inclusions in cytomegalovirus infection), when present, may be useful for distinguishing viral diseases from GVHD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The frequency with which viral eruptions cause skin eruptions in post-HCT patients is unclear. HHV-6B reactivation has been associated with increased risk of grades 2 through 4 acute GVHD [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eruption of lymphocyte recovery
         </strong>
         – Lymphocyte recovery describes the return of lymphocytes to the peripheral circulation following marrow ablative therapy. The eruption of lymphocyte recovery is a self-limited skin exanthem associated with transient fever that was first described following recovery of lymphocyte counts in patients treated with chemotherapy [
         <a href="#rid25">
          25
         </a>
         ]. Unlike GVHD, gastrointestinal and hepatic abnormalities do not occur. Histopathologic examination typically demonstrates a superficial perivascular mononuclear cell infiltrate [
         <a href="#rid25">
          25
         </a>
         ]; however, histopathologic findings resembling those of grade 1 or 2 acute GVHR also have been observed [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acral erythema
         </strong>
         –
         <strong>
         </strong>
         Acral erythema (also known as palmoplantar erythrodysesthesia) is a complication of chemotherapy  (
         <a class="graphic graphic_picture graphicRef77501 graphicRef79857" href="/z/d/graphic/77501.html" rel="external">
          picture 7A-B
         </a>
         ).
         <strong>
         </strong>
         Like acute GVHD, acral erythema affects the palms and soles. Painful symmetrical edema and erythema occur; blistering and desquamation also may develop. (See
         <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">
          "Cutaneous adverse effects of conventional chemotherapy agents", section on 'Toxic erythema of chemotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxic epidermal necrolysis
         </strong>
         – Severe cases of acute GVHD share clinical and histopathologic features with toxic epidermal necrolysis, a severe skin reaction typically induced by a medication  (
         <a class="graphic graphic_picture graphicRef59418 graphicRef68458 graphicRef82150 graphicRef66134" href="/z/d/graphic/59418.html" rel="external">
          picture 8A-D
         </a>
         ). Toxic epidermal necrolysis typically begins with dusky erythematous macules that rapidly progress to extensive blistering and desquamation. Histopathologic examination of established lesions reveals subepidermal bullae and full-thickness epidermal necrosis. Differentiation between severe GVHD and toxic epidermal necrolysis is sometimes impossible. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Engraftment syndrome
         </strong>
         – Engraftment syndrome presents with a cutaneous eruption that mimics acute GVHD, fever without identifiable infectious source, and signs of capillary leak syndrome (eg, noncardiogenic pulmonary edema with hypoxia, weight gain) [
         <a href="#rid27">
          27
         </a>
         ]. Engraftment syndrome is most commonly considered a phenomenon of autologous HCT; however, it may also occur after allogenic HCT [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation dermatitis
         </strong>
         –
         <strong>
         </strong>
         Acute radiation dermatitis presents with cutaneous erythema, desquamation, blistering, or cutaneous necrosis. The histopathologic features are similar to acute GVHD, demonstrating vacuolization of the basal layer, apoptotic keratinocytes, satellite cell necrosis, and a superficial perivascular lymphocytic infiltrate. (See
         <a class="medical medical_review" href="/z/d/html/13668.html" rel="external">
          "Radiation dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erythema multiforme
         </strong>
         –
         <strong>
         </strong>
         Erythema multiforme is an immune-mediated disorder that most commonly occurs in the setting of herpes simplex virus infection  (
         <a class="graphic graphic_picture graphicRef62370 graphicRef57894 graphicRef51037" href="/z/d/graphic/62370.html" rel="external">
          picture 9A-C
         </a>
         ). Like acute GVHD, the histopathologic findings in erythema multiforme include necrotic keratinocytes, subepidermal clefts, and vacuolization of basal keratinocytes. The clinical identification of target and targetoid lesions, suggests a diagnosis of erythema multiforme. (See
         <a class="medical medical_review" href="/z/d/html/5559.html" rel="external">
          "Erythema multiforme: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18902850">
         <span class="h1">
          CHRONIC CUTANEOUS GRAFT-VERSUS-HOST DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic GVHD is a major cause of morbidity and mortality in long-term survivors of allogeneic hematopoietic cell transplantation (HCT). The skin is the most common site of involvement; however, nearly all organ systems may be affected  (
         <a class="graphic graphic_table graphicRef115901" href="/z/d/graphic/115901.html" rel="external">
          table 2
         </a>
         ). Chronic GVHD may occur with or without a history of acute GVHD [
         <a href="#rid2">
          2,3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2692996">
         <span class="h2">
          Clinical manifestations
         </span>
        </p>
        <p class="headingAnchor" id="H733638">
         <span class="h3">
          Skin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traditionally, chronic cutaneous GVHD has been classified as lichen planus-like or sclerotic (resembling scleroderma); however, many different clinical presentations of chronic GVHD are now recognized, reflecting a spectrum of epidermal and dermal (sclerotic) changes.
        </p>
        <p>
         Cutaneous and extracutaneous diagnostic criteria for chronic GVHD composed by a panel of experts in the National Institutes of Health Consensus project have been published [
         <a href="#rid1">
          1
         </a>
         ]. The panel designated lichen planus-like lesions, sclerotic skin manifestations, and poikilodermatous changes in the skin as clinical features that are diagnostic of chronic GVHD.
        </p>
        <p class="headingAnchor" id="H877759">
         <span class="h4">
          Lichen planus-like lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lichen planus-like chronic GVHD presents as erythematous to violaceous papules or plaques with a predilection for the dorsal hands and feet, forearms, and trunk  (
         <a class="graphic graphic_picture graphicRef55336" href="/z/d/graphic/55336.html" rel="external">
          picture 10
         </a>
         ). Fine scale may be present. Lesions resemble true lichen planus. Patients may complain of pruritus. (See
         <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">
          "Lichen planus"
         </a>
         .)
        </p>
        <p>
         Lichen planus-like chronic GVHD also can occur in a follicular distribution, mimicking the appearance of keratosis pilaris [
         <a href="#rid1">
          1
         </a>
         ]. Lesions in sites of herpes zoster scars or following Blaschko's lines have been reported [
         <a href="#rid29">
          29
         </a>
         ]. Although lichen planus-like GVHD is sometimes considered an earlier form of GVHD than sclerotic GVHD, it is not a prerequisite for the development of sclerotic disease manifestations [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3310574237">
         <span class="h4">
          Sclerotic manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sclerosis is a common manifestation of chronic GVHD [
         <a href="#rid31">
          31-33
         </a>
         ]. A retrospective study of 977 patients who received systemic treatment for chronic GVHD after a first allogenic HCT found that 20 percent of patients had sclerosis (defined by documentation of cutaneous sclerosis, fasciitis, or joint contracture in the medical record) by three years after initial systemic treatment for chronic GVHD [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Sclerotic skin manifestations of chronic GVHD can develop in sites of resolving lichen planus-like lesions or in areas of previously normal skin. Lesions may occur in any location. The depth at which cutaneous sclerosis occurs determines the clinical presentation [
         <a href="#rid34">
          34
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morpheaform
         </strong>
         – Morphea-like chronic GVHD results from sclerosis that primarily involves the dermis. This variant usually presents with firm, hyperpigmented, hypopigmented, or skin-colored plaques  (
         <a class="graphic graphic_picture graphicRef52693" href="/z/d/graphic/52693.html" rel="external">
          picture 11
         </a>
         ). Affected skin often has a shiny appearance and demonstrates hair loss secondary to elimination of adnexal structures. (See
         <a class="medical medical_review" href="/z/d/html/13776.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6399.html" rel="external">
          "Juvenile localized scleroderma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Unlike systemic sclerosis, body surface area involvement in sclerotic GVHD often is discontinuous. In some cases, lesions may preferentially appear in sites of skin trauma (Koebner phenomenon) [
         <a href="#rid35">
          35,36
         </a>
         ]. In one series of 58 patients with sclerotic chronic GVHD, 11 (19 percent) exhibited strikingly linear lesions in the waistband area [
         <a href="#rid35">
          35
         </a>
         ]. Extensive involvement of the chest wall may lead to respiratory symptoms secondary to restricted chest expansion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lichen sclerosus-like
         </strong>
         – When sclerosis occurs in the superficial dermis, lesions resemble lichen sclerosus, a dermatosis characterized by epidermal atrophy and superficial dermal fibrosis. Lichen sclerosus-like lesions are typically found on the upper back as white or gray, thin plaques with accentuated dermatoglyphics. (See
         <a class="medical medical_review" href="/z/d/html/15838.html" rel="external">
          "Extragenital lichen sclerosus: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deep sclerosis/eosinophilic fasciitis-like
         </strong>
         – Deep sclerosis may also occur. Subcutaneous fibrosis results in a cellulite-like rippled appearance to the skin due to thickening of the fibrous septae within fat, particularly on the medial arms and thighs  (
         <a class="graphic graphic_picture graphicRef64464" href="/z/d/graphic/64464.html" rel="external">
          picture 12
         </a>
         ). Fascial involvement tends to occur late in the chronic period, and may lead to the appearance of prominent linear demarcations, often referred to as the "groove sign," and contractures that limit range of motion  (
         <a class="graphic graphic_picture graphicRef76298" href="/z/d/graphic/76298.html" rel="external">
          picture 13
         </a>
         ). In eosinophilic-fasciitis-like cases, these findings of deep sclerosis are often accompanied by pain and edema [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7547.html" rel="external">
          "Eosinophilic fasciitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The development of bullae or ulcerations may complicate sclerotic disease [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">
          "Pathogenesis of graft-versus-host disease (GVHD)"
         </a>
         .)
        </p>
        <p>
         Additional studies are necessary to clarify the risk factors and prognostic implications for sclerosis in chronic GVHD. In the retrospective study of 977 patients described above, a significant increase in risk for sclerosis was observed among patients who received a mobilized blood cell graft compared with a bone marrow graft and patients who received total body irradiation (TBI) exposure &gt;450 Gy in the conditioning regimen compared with no TBI [
         <a href="#rid31">
          31
         </a>
         ]. Unexpectedly, use of an HLA-mismatched donor was associated with a reduced risk of sclerosis, as was the use of an ABO-mismatched donor. Sclerosis was not associated with risk for subsequent mortality or recurrent malignancy. A significant association between sclerotic chronic GVHD and TBI also was demonstrated in a separate study of 206 patients with primarily severe chronic GVHD [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3472768246">
         <span class="h4">
          Poikiloderma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Poikiloderma describes the combination of atrophy, hypopigmentation, and hyperpigmentation in the skin. Poikilodermatous skin changes in chronic GVHD appear as patches with mottled pigmentation and telangiectasias  (
         <a class="graphic graphic_picture graphicRef66942" href="/z/d/graphic/66942.html" rel="external">
          picture 14
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H877975">
         <span class="h4">
          Other cutaneous findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to poikiloderma, other pigment disorders may occur in chronic GVHD, including the appearance of depigmented, hypopigmented, and hyperpigmented areas. Hyperpigmentation may occur in a widespread, leopard-skin like pattern. In one series of 17 patients with sclerotic chronic GVHD, 10 (59 percent) had a history of the appearance of multiple hyperpigmented macules with fine scale prior to the development of sclerotic lesions [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Widespread eczematous lesions and malar eruptions resembling systemic lupus erythematosus have been reported as histopathologically confirmed manifestations of chronic GVHD in small series of patients [
         <a href="#rid37">
          37,38
         </a>
         ]. An atopic dermatitis-like presentation also has been documented [
         <a href="#rid39">
          39
         </a>
         ]. Other cutaneous findings associated with chronic GVHD include hypohidrosis, ichthyosis, erythema, pruritus, and maculopapular eruptions [
         <a href="#rid1">
          1
         </a>
         ]. Cutaneous vascular lesions, termed "graft-versus-host disease-associated angiomatosis," as well as calcinosis cutis may develop in patients with chronic GVHD, particularly at sites of long-standing skin sclerosis  (
         <a class="graphic graphic_picture graphicRef127134 graphicRef127135" href="/z/d/graphic/127134.html" rel="external">
          picture 15A-B
         </a>
         ) [
         <a href="#rid40">
          40,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13756.html" rel="external">
          "Calcinosis cutis: Etiology and patient evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H733440">
         <span class="h3">
          Oral lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Forty-five to 83 percent of patients with chronic GVHD develop oral involvement  (
         <a class="graphic graphic_picture graphicRef73344 graphicRef82463 graphicRef61588" href="/z/d/graphic/73344.html" rel="external">
          picture 16A-C
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Lacy or reticulated white plaques that resemble Wickham's striae of lichen planus may occur on the tongue, buccal mucosa, lips, or palate. Hyperkeratotic plaques, mucosal erythema, erosions, and ulceration can also occur. Associated pain may inhibit oral intake [
         <a href="#rid42">
          42
         </a>
         ]. In patients with sclerotic GVHD, perioral sclerosis can lead to restricted oral aperture, further complicating dental hygiene and nutritional status.
        </p>
        <p>
         In addition, patients may suffer from sicca symptoms resembling those that occur in Sjögren's disease secondary to impairment of salivary gland function. Mucoceles, which are fluid-filled smooth nodules on the oral mucosa that represent accumulations of sialomucin from minor salivary glands in the oral mucosa, may also occur  (
         <a class="graphic graphic_picture graphicRef70332" href="/z/d/graphic/70332.html" rel="external">
          picture 17
         </a>
         ). Mucoceles result from obstruction of the salivary duct, and are thought to be related to salivary gland inflammation associated with chronic GVHD [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Oral verruciform xanthoma (mucosal plaques characterized histologically by epithelial hyperplasia and foamy macrophages) is a rare finding that has been documented in a few patients with chronic GVHD [
         <a href="#rid43">
          43
         </a>
         ]. Oral verruciform xanthomas may also occur on normal mucosa, or in the setting of oral lichen planus or other inflammatory diseases.
        </p>
        <p class="headingAnchor" id="H733454">
         <span class="h3">
          Hair disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Scarring or nonscarring alopecia or scaly papules on the scalp may occur in chronic GVHD, but are not sufficient to establish the diagnosis in the absence of other findings consistent with GVHD [
         <a href="#rid1">
          1,44
         </a>
         ]. Thinning hair, patchy hair loss, coarse or dull hair, and premature graying may occur. Alopecia areata and other autoimmune skin conditions such as vitiligo have been reported in the GVHD setting [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H733461">
         <span class="h3">
          Nail disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of nail abnormalities ranging from mild nail dystrophy to total nail loss (anonychia) may occur  (
         <a class="graphic graphic_picture graphicRef71229" href="/z/d/graphic/71229.html" rel="external">
          picture 18
         </a>
         ). Examples of associated nail abnormalities include longitudinal ridging, splitting or brittle nails, onycholysis (separation of the nail plate from the nail bed), and pterygium (abnormal adherence of the nail plate to the proximal nail fold or hyponychium).
        </p>
        <p class="headingAnchor" id="H733468">
         <span class="h3">
          Ocular and genital mucosa
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammation of the conjunctiva, pseudomembranous or cicatricial conjunctivitis, and keratoconjunctivitis sicca (dry eye) syndrome may occur in patients with chronic GVHD. Symptoms of ocular irritation, pain, or visual changes may accompany these findings. Vulvar or vaginal erosions, lichen planus-like lesions, or sclerosis leading to labial resorption or tissue agglutination may also occur in affected females. Balanitis and phimosis may develop in males.
        </p>
        <p class="headingAnchor" id="H1871191981">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tissue biopsy is recommended to confirm chronic GVHD in the absence of diagnostic clinical findings [
         <a href="#rid1">
          1,46
         </a>
         ]. A summary of the common and diagnostic clinical features of chronic GVHD, as defined by the National Institutes of Health Consensus Project, is provided in a table  (
         <a class="graphic graphic_table graphicRef115901" href="/z/d/graphic/115901.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">
          "Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Diagnosis and classification'
         </a>
         .)
        </p>
        <p>
         The histopathologic changes in chronic GVHD vary according to the type of skin involvement. The classic findings in lichen planus-like and sclerotic lesions are discussed below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lichen planus-like lesions
         </strong>
         – Lichen planus-like papules and plaques reveal findings that resemble lichen planus, with hyperkeratosis, hypergranulosis, acanthosis, saw-tooth rete, interface dermatitis, and dyskeratotic keratinocytes [
         <a href="#rid46">
          46
         </a>
         ]. Periadnexal inflammation, particularly around eccrine glands is evident in some cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sclerotic lesions
         </strong>
         – Sclerotic skin involvement may or may not demonstrate overlying epidermal changes of lichen planus-like disease. Lichen sclerosus-like lesions characteristically show epidermal atrophy with edema and homogenization of collagen in the superficial dermis [
         <a href="#rid2">
          2
         </a>
         ]. Morpheaform lesions demonstrate thickened collagen bundles in the dermis with loss of adnexal structures, and in the absence of epidermal changes, may be indistinguishable from specimens from true morphea or systemic sclerosis. As in these other disorders, specimens from lesions of sclerotic chronic GVHD often have a square or "box car" shape to the biopsy. Sclerotic GVHD involving the subcutaneous tissue demonstrates a lymphocytic infiltrate near the interface of dermis and fat with thickening of the septae.
        </p>
        <p>
        </p>
        <p>
         A 4 mm punch biopsy is sufficient for the evaluation of lichen planus-like, lichen sclerosus-like, and most morpheaform lesions. Deep incisional biopsy may be necessary to evaluate for fascial involvement. Magnetic resonance imaging (MRI) also may have value for the diagnosis of subcutaneous disease and fasciitis [
         <a href="#rid47">
          47,48
         </a>
         ]. The efficacy of MRI for long-term monitoring of disease activity is unclear.
        </p>
        <p>
         Various scales have been used to assess the severity of skin involvement in chronic GVHD, most of which have not been validated. A multicenter prospective study that evaluated several assessment scales found that the National Institutes of Health composite 0 to 3 skin score correlated with both the clinician and patient perceptions of disease improvement or worsening [
         <a href="#rid49">
          49
         </a>
         ]. The Lee skin symptom score, a scale based on the patient's assessment also correlated with these factors. Both scales were useful for assessing prognosis. In a separate study, the National Institutes of Health chronic GVHD Oral Mucosal Score was found to associate with patient-reported oral pain and sensitivity [
         <a href="#rid50">
          50
         </a>
         ]. These scoring systems may be helpful tools for evaluating patients with chronic cutaneous GVHD in research trials and clinical practice.
        </p>
        <p class="headingAnchor" id="H733020">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several disorders share clinical and histopathologic features with chronic GVHD:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lichen planus-like lesions
         </strong>
         –
         <strong>
         </strong>
         The clinical and histopathologic features of lichen planus-like GVHD closely resemble lichen planus. Lesions of GVHD may be less angular and may have less well-defined margins than lichen planus [
         <a href="#rid4">
          4
         </a>
         ]. The flexural wrists and shins are classic sites for true lichen planus  (
         <a class="graphic graphic_picture graphicRef76383 graphicRef63590" href="/z/d/graphic/76383.html" rel="external">
          picture 19A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">
          "Lichen planus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lichenoid drug eruptions and pityriasis lichenoides chronica are additional disorders that may present with widespread erythematous papules and interface dermatitis  (
         <a class="graphic graphic_picture graphicRef80165 graphicRef59258 graphicRef71210" href="/z/d/graphic/80165.html" rel="external">
          picture 20A-C
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/15763.html" rel="external">
          "Lichenoid drug eruption (drug-induced lichen planus)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15287.html" rel="external">
          "Pityriasis lichenoides chronica"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sclerotic lesions
         </strong>
         – Sclerotic lesions can mimic lichen sclerosus, morphea, systemic sclerosis, and eosinophilic fasciitis  (
         <a class="graphic graphic_picture graphicRef74154 graphicRef56113 graphicRef82198 graphicRef50218" href="/z/d/graphic/74154.html" rel="external">
          picture 21A-D
         </a>
         ). Of note, the distal to proximal progression of cutaneous sclerosis on the extremities that is characteristic of systemic sclerosis typically is not observed in chronic GVHD. Radiation-induced fibrosis and nephrogenic fibrosing dermopathy can also present with induration and thickening of the skin. The possibility of nephrogenic fibrosing dermopathy should be considered in patients with renal failure. (See
         <a class="medical medical_review" href="/z/d/html/13776.html" rel="external">
          "Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6399.html" rel="external">
          "Juvenile localized scleroderma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7547.html" rel="external">
          "Eosinophilic fasciitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1955.html" rel="external">
          "Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Poikiloderma
         </strong>
         –
         <strong>
         </strong>
         Poikiloderma can occur in a variety of disorders, most commonly on the lateral necks of fair-skinned individuals as poikiloderma of Civatte, a condition that is thought to be related to chronic sun exposure  (
         <a class="graphic graphic_picture graphicRef81779" href="/z/d/graphic/81779.html" rel="external">
          picture 22
         </a>
         ). Additional disorders that may present with poikiloderma include dermatomyositis, systemic lupus erythematosus, Rothmund-Thompson syndrome, Bloom syndrome, and poikiloderma vasculare atrophicans in the setting of parapsoriasis or cutaneous T cell lymphoma  (
         <a class="graphic graphic_picture graphicRef63888" href="/z/d/graphic/63888.html" rel="external">
          picture 23
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3496567">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3886460">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic therapy is generally required for the management of patients with acute GVHD. Topical corticosteroids may provide improvement in patients with limited skin disease and no internal involvement. (See
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
         Phototherapy may be an additional treatment option for acute cutaneous GVHD. In retrospective studies, psoralen plus ultraviolet A (PUVA) and narrowband ultraviolet B phototherapy have been associated with improvement in acute cutaneous GVHD that was refractory to systemic glucocorticoid therapy or that flared upon glucocorticoid tapering [
         <a href="#rid51">
          51,52
         </a>
         ]. Prior to a recommendation for the routine use of phototherapy, further study is necessary to determine the long-term safety and efficacy of phototherapy in this population.
        </p>
        <p>
         Topical corticosteroids and topical calcineurin inhibitors may have some benefit for patients with limited nonsclerotic chronic GVHD [
         <a href="#rid53">
          53
         </a>
         ]. Phototherapy and systemic therapies are the mainstays of treatment for patients with sclerotic lesions. (See
         <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">
          "Treatment of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
         Although oral
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         is used for the treatment of acute and chronic GVHD, additional study is necessary to determine the role of topical Janus kinase (JAK) inhibitors in GVHD. In a case report, treatment with ruxolitinib was associated with marked hair regrowth in a patient with alopecia universalis and chronic GVHD [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease", section on 'Ruxolitinib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">
          "Treatment of chronic graft-versus-host disease", section on 'Ruxolitinib'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H878120">
         <span class="h2">
          Ancillary measures in chronic graft-versus-host disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic cutaneous GVHD benefit from preventive skin care recommendations, including skin cancer surveillance, monitoring for adverse effects of topical corticosteroids, management of pruritus, and wound care and infection control measures [
         <a href="#rid53">
          53,55
         </a>
         ]. Guidelines for ancillary therapy and supportive care of chronic GVHD were proposed by the original National Institutes of Health (NIH) Consensus Development Project and revised in 2015 [
         <a href="#rid55">
          55,56
         </a>
         ]. Recommendations included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Photoprotection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular use of emollients on intact skin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Careful use of topical corticosteroids to reduce risk for cutaneous atrophy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of topical or systemic antipruritic agents when needed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wound management
        </p>
        <p>
        </p>
        <p>
         Cutaneous squamous cell carcinoma (SCC) is a potential long-term complication of hematopoietic cell transplant (HCT); the development of multiple cutaneous SCCs has been reported in patients chronic GVHD [
         <a href="#rid57">
          57-59
         </a>
         ]. Immunosuppression, PUVA phototherapy, and chronic wounds are associated with elevated risk for cutaneous SCC, and may contribute to the development of SCC in this population. Patients should be encouraged to engage in sun protective practices, including the use of broad spectrum sunscreens, sun protective clothing, and sun avoidance [
         <a href="#rid55">
          55
         </a>
         ]. In addition, patients should be examined periodically for signs of skin cancer. (See
         <a class="medical medical_review" href="/z/d/html/3558.html" rel="external">
          "Secondary cancers after hematopoietic cell transplantation", section on 'Prevention and screening'
         </a>
         .)
        </p>
        <p>
         Daily use of emollients may reduce pruritus and may be beneficial for maintaining skin integrity [
         <a href="#rid55">
          55
         </a>
         ]. Ointment or creams, rather than less-occlusive lotion formulations, are preferred. Urea-containing compounds (3 to 10%) are efficacious for hydration but may be irritating to nonintact or inflamed skin and in young children [
         <a href="#rid56">
          56
         </a>
         ]. Topical antipruritic agents such as
         <a class="drug drug_general" data-topicid="10068" href="/z/d/drug information/10068.html" rel="external">
          pramoxine-hydrocortisone
         </a>
         or menthol-containing lotions or creams may also be beneficial for pruritus. In patients with significant symptoms, oral antipruritics such as
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         may be used.
        </p>
        <p>
         For patients with active cutaneous involvement involving the epidermis (eg, lichen planus-like lesions), medium-potency topical corticosteroids (
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         0.1% cream or ointment) can be applied on the trunk and extremities [
         <a href="#rid56">
          56
         </a>
         ]. When topical corticosteroids, particularly high-potency agents, are used, patients should be monitored for signs of cutaneous atrophy. Low-potency agents, such as
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         1 to 2.5% or
         <a class="drug drug_general" data-topicid="9331" href="/z/d/drug information/9331.html" rel="external">
          desonide
         </a>
         0.05%, should be used on areas at high risk for atrophy (face and intertriginous areas)  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         Spontaneous ulceration can occur in patients with sclerotic chronic GVHD. Areas of skin breakdown should be assessed for the possibility of infection or malignancy and cultured, biopsied, and treated as appropriate [
         <a href="#rid55">
          55
         </a>
         ]. Chronic wounds in the setting of GVHD may be challenging to heal, and referral to a wound care center may be beneficial. Plastic surgery consultation is useful in some cases. Improvement in friable lesions of GVHD-associated angiomatosis with use of topical
         <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">
          timolol
         </a>
         0.5% ophthalmic solution, an effective treatment for infantile hemangiomas, has been documented in a case report [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5792.html" rel="external">
          "Infantile hemangiomas: Management", section on 'Topical beta blockers'
         </a>
         .)
        </p>
        <p>
         Patients should be educated regarding early signs of skin sclerosis, such as skin tightness, edema, and reduced range of motion, and should be instructed to seek care if these symptoms occur. Serial clinical photography and range of motion assessment are useful for documenting changes in skin activity over time in patients with sclerotic chronic GVHD.
        </p>
        <p class="headingAnchor" id="H2545317179">
         <span class="h2">
          Oral lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical high-potency corticosteroids are often used for the treatment of oral GVHD [
         <a href="#rid7">
          7
         </a>
         ]. Solutions are used for generalized involvement, whereas other vehicles, such as gels, can be applied to individual lesions with gauze and left in place for 10 to 15 minutes. Oral candidiasis is not uncommon, and some patients may require ongoing fungal prophylaxis [
         <a href="#rid56">
          56
         </a>
         ]. Supportive interventions for patients with oral chronic GVHD include encouraging good oral hygiene and utilizing of topical anesthetic agents, such as viscous
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , to reduce pain and facilitate oral intake.
        </p>
        <p>
         There are multiple reports of oral SCC in patients with chronic GVHD, and patients should be followed closely for the development of oral malignancies [
         <a href="#rid61">
          61
         </a>
         ]. Leukoplakia may be a benign manifestation of chronic GVHD or a precursor to oral SCC. Leukoplakia that fails to improve or worsens despite therapy should be biopsied [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Patients with xerostomia may benefit from salivary stimulants (sugarless gum or candy), oral lubricants or saliva substitutes, and topical
         <a class="drug drug_general" data-topicid="8462" href="/z/d/drug information/8462.html" rel="external">
          fluoride
         </a>
         to prevent tooth decay. Cholinergic agonists to stimulate saliva production (eg,
         <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">
          pilocarpine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8884" href="/z/d/drug information/8884.html" rel="external">
          cevimeline
         </a>
         ) may be useful in patients in whom the use of these agents is not contraindicated. (See
         <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">
          "Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"
         </a>
         .)
        </p>
        <p>
         No therapy is necessary for small, superficial mucoceles [
         <a href="#rid55">
          55
         </a>
         ]. Deep lesions that cause discomfort can be surgically excised.
        </p>
        <p class="headingAnchor" id="H978114559">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/132533.html" rel="external">
          "Society guideline links: Cutaneous graft-versus-host disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1072630089">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         –
         <strong>
         </strong>
         Graft-versus-host-disease (GVHD) is a common complication of hematopoietic cell transplant (HCT) that results from recognition of host antigens by immunocompetent cells from the donor. Cutaneous manifestations commonly occur in both acute and chronic GVHD. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute cutaneous graft-versus-host disease
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical manifestations
         </strong>
         –
         <strong>
         </strong>
         Acute GVHD usually begins with erythematous macules on the ears, palms, soles, neck, face, or upper back. Lesions subsequently become more generalized; severe cases exhibit erythroderma, bullae, and extensive epidermal necrosis. Little is known about oral involvement in acute GVHD. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diagnosis
         </strong>
         –
         <strong>
         </strong>
         Characteristic histopathologic findings in acute GVHD include vacuolization of the basal layer of the epidermis, a sparse lymphocytic dermal infiltrate, and apoptotic keratinocytes. Advanced lesions demonstrate subepidermal clefts and extensive epidermal necrosis. The value of skin biopsy in acute GVHD has been questioned. Biopsies can yield nonspecific results. In all cases, histopathologic findings require clinical correlation for proper interpretation. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A variety of disorders, including drug eruptions, viral exanthems, and toxic epidermolytic necrosis share clinical and/or histopathologic features with acute cutaneous GVHD. The possibility of other disorders must be considered in hematopoietic stem cell transplant patients who present with clinical or histopathologic findings suggestive of acute cutaneous GVHD. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic cutaneous graft-versus-host disease
         </strong>
         –
         <strong>
         </strong>
         Chronic GVHD presents with various morphologies involving the epidermis, dermis, or subcutaneous tissues. Lichen planus-like lesions resemble the dermatologic disease lichen planus, whereas sclerotic involvement may resemble morphea, lichen sclerosus, or eosinophilic fasciitis. Dyspigmentation and other cutaneous, hair, or nail abnormalities have been associated with chronic GVHD. Oral involvement is common. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ancillary measures for chronic cutaneous graft-versus-host disease
         </strong>
         –
         <strong>
         </strong>
         Patients with chronic GVHD may benefit from the use of emollients, topical or systemic antipruritic agents, or topical corticosteroids. Patients should also be followed closely for the development of cutaneous or oral squamous cell carcinoma. Agents to reduce oral pain or xerostomia are useful. (See
         <a class="local">
          'Ancillary measures in chronic graft-versus-host disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">
          "Treatment of chronic graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2168589737">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the National Institutes of Health or the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñas PF, Zaman S. Many faces of graft-versus-host disease. Australas J Dermatol 2010; 51:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goddard DS, Horn BN, McCalmont TH, Cordoro KM. Clinical update on graft-versus-host disease in children. Semin Cutan Med Surg 2010; 29:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas-Díez E, García-Díez A, Marín A, Fernández-Herrera J. Life-threatening graft-vs-host disease. Clin Dermatol 2005; 23:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman KJ, LeBoit PE, Farmer ER. Acute follicular graft-vs-host reaction. A distinct clinicopathologic presentation. Arch Dermatol 1988; 124:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imanguli MM, Alevizos I, Brown R, et al. Oral graft-versus-host disease. Oral Dis 2008; 14:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mays SR, Kunishige JH, Truong E, et al. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg 2007; 26:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung YT, Chen YW, Huang Y, et al. Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study. J Am Acad Dermatol 2023; 88:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsoi MS, Storb R, Jones E, et al. Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol 1978; 120:1485.
          </a>
         </li>
         <li class="breakAll">
          Weedon D. The lichenoid reaction pattern (interface dermatitis). In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.35.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerner KG, Kao GF, Storb R, et al. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc 1974; 6:367.
          </a>
         </li>
         <li class="breakAll">
          Sharp MT, Horn TD. Graft-versus-host disease. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al. (Eds), McGraw-Hill, 2008. p.258.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuykendall TD, Smoller BR. Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation. J Am Acad Dermatol 2003; 49:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou Y, Barnett MJ, Rivers JK. Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 2000; 136:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firoz BF, Lee SJ, Nghiem P, Qureshi AA. Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. Arch Dermatol 2006; 142:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drijkoningen M, De Wolf-Peeters C, Tricot G, et al. Drug-induced skin reactions and acute cutaneous graft-versus-host reaction: a comparative immunohistochemical study. Blut 1988; 56:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol 1997; 21:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev 2001; 53:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol 2011; 65:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra DE, McKee PH, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol 2004; 51:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel AR, Turner ML, Baird K, et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009; 15:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshikawa T, Ihira M, Ohashi M, et al. Correlation between HHV-6 infection and skin rash after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phan TL, Carlin K, Ljungman P, et al. Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018; 24:2324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn TD, Redd JV, Karp JE, et al. Cutaneous eruptions of lymphocyte recovery. Arch Dermatol 1989; 125:1512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer DJ, Hood AF, Horn TD. Histologic comparison of autologous graft-vs-host reaction and cutaneous eruption of lymphocyte recovery. Arch Dermatol 1993; 129:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carreras E, Fernández-Avilés F, Silva L, et al. Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant 2010; 45:1417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaffer JV. The changing face of graft-versus-host disease. Semin Cutan Med Surg 2006; 25:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñas PF, Jones-Caballero M, Aragüés M, et al. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol 2002; 138:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inamoto Y, Storer BE, Petersdorf EW, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 2013; 121:5098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skert C, Patriarca F, Sperotto A, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006; 91:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martires KJ, Baird K, Steinberg SM, et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011; 118:4250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaffer JV, McNiff JM, Seropian S, et al. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 2005; 53:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel AR, Pavletic SZ, Turner ML, Cowen EW. The isomorphic response in morphealike chronic graft-vs-host disease. Arch Dermatol 2008; 144:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martires KJ, Baird K, Citrin DE, et al. Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses. Arch Dermatol 2011; 147:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creamer D, Martyn-Simmons CL, Osborne G, et al. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. Arch Dermatol 2007; 143:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goiriz R, Peñas PF, Delgado-Jiménez Y, et al. Cutaneous lichenoid graft-versus-host disease mimicking lupus erythematosus. Lupus 2008; 17:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei J, Zhang Y, Xu H, et al. Atopic dermatitis-like presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 2013; 69:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaffenberger BH, Zuo RC, Gru A, et al. Graft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity. J Am Acad Dermatol 2014; 71:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saardi KM, Rosenstein RK, Anadkat MJ, et al. Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. JAMA Dermatol 2020; 156:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imanguli MM, Pavletic SZ, Guadagnini JP, et al. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahrabi Farahani S, Treister NS, Khan Z, Woo SB. Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature. Head Neck Pathol 2011; 5:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuo RC, Naik HB, Steinberg SM, et al. Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. JAMA Dermatol 2015; 151:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006; 12:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark J, Yao L, Pavletic SZ, et al. Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease. Arch Dermatol 2009; 145:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oda K, Nakaseko C, Ozawa S, et al. Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT. Bone Marrow Transplant 2009; 43:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012; 120:2545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassim CW, Fassil H, Mays JW, et al. Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures. Bone Marrow Transplant 2014; 49:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furlong T, Leisenring W, Storb R, et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldstein JV, Bolaños-Meade J, Anders VL, Abuav R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol 2011; 65:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marks C, Stadler M, Häusermann P, et al. German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. Br J Dermatol 2011; 165:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borg MA, Shalabi RA, Childs R, Wells BC. Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib. JAMA Dermatol 2018; 154:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015; 21:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altman JS, Adler SS. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease. J Am Acad Dermatol 1994; 31:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SJ, Jackson GH, Reynolds NJ, Lawrence CM. Chronic cutaneous graft-versus-host disease associated with multiple cutaneous squamous cell carcinomas. Clin Exp Dermatol 2006; 31:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howe NR, Lang PG. Squamous cell carcinoma of the sole in a patient with chronic graft-vs-host disease. Arch Dermatol 1988; 124:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bashline BR, Mortazie M, Schapiro B, Fivenson D. Graft-versus-host Disease-associated Angiomatosis Treated With Topical Timolol Solution. Wounds 2016; 28:E18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demarosi F, Soligo D, Lodi G, et al. Squamous cell carcinoma of the oral cavity associated with graft versus host disease: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:63.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13760 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16338616" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20148830" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Many faces of graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20579598" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical update on graft-versus-host disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15896544" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Life-threatening graft-vs-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3284466" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acute follicular graft-vs-host reaction. A distinct clinicopathologic presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7581076" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : 1994 Consensus Conference on Acute GVHD Grading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18593456" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Oral graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18070682" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Approach to the morbilliform eruption in the hematopoietic transplant patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36280000" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26718" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26718" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4155153" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4155153" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14639388" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10871932" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16490845" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2963669" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Drug-induced skin reactions and acute cutaneous graft-versus-host reaction: a comparative immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9298874" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11546834" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cutaneous drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21641677" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15389188" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19203729" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11498748" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Correlation between HHV-6 infection and skin rash after allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29684567" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2684020" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cutaneous eruptions of lymphocyte recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8323305" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Histologic comparison of autologous graft-vs-host reaction and cutaneous eruption of lymphocyte recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11436099" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Engraftment syndrome following hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20062097" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17174839" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The changing face of graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12071820" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23547053" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16461315" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21791415" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16198778" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794477" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The isomorphic response in morphealike chronic graft-vs-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21931046" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17875877" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18539715" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cutaneous lichenoid graft-versus-host disease mimicking lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23375455" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Atopic dermatitis-like presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24993601" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Graft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32432645" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16448918" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Chronic graft versus host disease of oral mucosa: review of available therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21305367" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25529383" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25207994" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16399567" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19687424" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18762758" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22773386" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23995099" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12014809" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21616558" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21466534" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30285060" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16545722" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25838185" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8077484" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16681614" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Chronic cutaneous graft-versus-host disease associated with multiple cutaneous squamous cell carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3401029" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Squamous cell carcinoma of the sole in a patient with chronic graft-vs-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27191176" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Graft-versus-host Disease-associated Angiomatosis Treated With Topical Timolol Solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15953918" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Squamous cell carcinoma of the oral cavity associated with graft versus host disease: report of a case and review of the literature.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
